Skip to main content
. 2022 Jan 13;23(2):826. doi: 10.3390/ijms23020826

Figure 2.

Figure 2

Tumor immune infiltrates associated with SBRT and SBRT + immunotherapy: (a) representative IHC images of immune cell infiltrates, pre-treatment and post-treatment, for tumors treated with SBRT or SBRT + immunotherapy; (b) fold change in percent positive immune cell density post-treatment relative to pre-treatment for tumors treated with SBRT or SBRT + immunotherapy. * p = 0.025, ** p = 0.008 (SBRT: n = 4; SBRT and immunotherapy: n = 3).